The FDA RMAT meeting outcome is a transformative catalyst — a single-arm pivotal trial path dramatically de-risks SENTI-202 registration. The Donor X biomarker discovery (50% cCR vs 12.5%) significantly improves the probability of success. However, with only $8.9M cash and $7.5M quarterly burn, the company needs the $10M initial tranche to close. Monitor for: (1) closing of the $10M tranche, (2) initiation of the pivotal trial, (3) additional Donor X efficacy data. The $30M ATM overhang caps near-term upside. Position for weeks-to-months horizon as pivotal trial details emerge.
Price Chart
Executive Summary
Senti Bio reported Q1 2026 results with net loss of $4.2M ($0.14/share) vs $14.1M ($1.41/share) in Q1 2025, driven by a $6.9M lease modification gain and lower operating expenses. Cash burn improved to $7.5M from $14.1M YoY. The critical catalyst is the positive FDA RMAT meeting supporting a single-arm pivotal trial for SENTI-202 in RR AML, combined with identification of a Donor X phenotype that triples cCR rates (50% vs 12.5%). A $40M convertible note facility (initial $10M tranche) provides funding runway but adds dilution risk. The $30M market cap company has $8.9M cash and a $30M ATM overhang from the prior 424B5 filing.
Key Financial Metrics
Key Facts
- Positive FDA RMAT meeting supports single-arm pivotal trial path for SENTI-202 registration in RR AML
- Donor X phenotype identified: 50% cCR (7/14) vs 12.5% (1/8) without; all future manufacturing to use Donor X
- Durable MRD-negative responses: all CR/CRh responders from ASH 2025 data cut maintain remission with 7 additional months follow-up (longest 21+ months)
- Up to $40M senior secured convertible note facility from Celadon Partners; initial $10M tranche expected May 2026
- Net loss improved to $4.2M ($0.14/share) from $14.1M ($1.41/share) YoY, including $6.9M non-recurring lease modification gain
- Cash burn reduced to $7.5M from $14.1M YoY; cash $8.9M at March 31, 2026 vs $16.4M at December 31, 2025
- Contingent value rights tied to SENTI-202 milestones could provide up to $60M additional value
- Prior 424B5 ATM program has ~$6.0M remaining unsold (~21% of $29M market cap)
Financial Impact
Q1 2026 net loss $4.2M vs $14.1M YoY; cash burn $7.5M vs $14.1M; $8.9M cash on hand; up to $40M convertible note facility with $10M initial tranche
Risk Factors
- Only $8.9M cash on hand with $7.5M quarterly burn — needs the $10M convertible tranche to close to extend runway
- Prior 424B5 ATM has ~$6.0M unsold (~21% of market cap) creating ongoing dilution overhang
- Convertible notes add debt and potential future dilution upon conversion
- Phase 1 data is still early (n=22); pivotal trial execution risk remains
- Donor X phenotype found in only 50% of donors — manufacturing scalability not yet proven at commercial scale
- Single-arm pivotal trial design may face FDA scrutiny on endpoint selection and comparator adequacy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-034834 |
| Exhibit: ex992sntifdameeting20260514.htm | 0001628280-26-034834 |
| Document: snti-20260514.htm | 0001628280-26-034834 |
| Document: 0001628280-26-034834-index-headers.html | 0001628280-26-034834 |
| Document: 0001628280-26-034834-index.html | 0001628280-26-034834 |
| Document: 0001628280-26-034834.txt | 0001628280-26-034834 |
| 8-K Data (Synthetic) | 0001628280-26-034834 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1751 (−27.28%) |
Oct 13, 2026 12d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1751 (+27.28%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1751 (+46.83%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1751 (+46.83%) |
Sep 22, 2026 4w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1751 (+44.52%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1751 (+42.78%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1751 (−47.35%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1751 (+47.35%) |
Aug 20, 2026 9w ago | 8-K | $0.3886 $0.3770 | ▲ +2.99% | ▲ +3.46% | $0.1751 (+54.94%) |
Jul 16, 2026 14w ago | S-3/A | $0.4597 $0.4266 | ▲ +7.20% | ▲ +5.53% | $0.1751 (+61.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers